Skip to content

PRX003 for Psoriasis and Other Inflammatory Diseases

Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases. Prothena focuses on therapeutic monoclonal antibodies directed specifically against disease-causing proteins, and its antibody-based product candidates may be useful for treating a number of potential indications, including: NEOD001 for the potential treatment of AL amyloidosis; PRX002 for the potential treatment of Parkinson’s disease or other related synucleinopathies; and PRX003 for the potential treatment of psoriasis and other inflammatory diseases. PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule (MCAM) for the potential treatment of psoriasis and other inflammatory diseases. PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule (MCAM) for the potential treatment of psoriasis and other inflammatory diseases.

PRX003 for Psoriasis and Other Inflammatory Diseases 2PRX003 may be useful for treating a variety of inflammatory diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, sarcoidosis, uveitis, giant cell arteritis, and Behcet’s disease. These statements relate to, among other things, PRX003’s method of action and whether it will be useful for treating a variety of inflammatory diseases. PRX 003 is in preclinical trials for other inflammatory diseases. Topical psoriasis treatments (other than low-potency topical corticosteroids or emollients, which are permitted during the study) within 2 weeks.

Because of the visual, defined nature of psoriasis, Prothena expects to be able to rapidly assess the biological activity of PRX003 and establish a clinical foundation to inform the strategic development pathway for psoriasis and other indications in inflammatory disease. Because of the visual, defined nature of psoriasis, Prothena expects to be able to rapidly assess the biological activity of PRX003 and establish a clinical foundation to inform the strategic development pathway for psoriasis and other indications in inflammatory disease. Presented preclinical data for PRX003 at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2016 Annual Meeting demonstrating the ability of PRX003 to inhibit migration of disease-causing immune cells. The first two programs target the amyloid proteins implicated in several diseases including AL amyloidosis through NEOD001 and Parkinson’s disease through PRX002 and our third program PRX003 targets the cellular traffic involved in psoriasis and other inflammatory diseases. Prothena Announces First Human Dosed in Phase I Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases Prothena Corporation plc announced the successful first human dosing in a Phase I clinical trial of its proprietary protein immunotherapy, PRX003.

Prothena To Present Preclinical Data For Prx003 At 2016 Aaaai Annual Meeting

Prothena Corporation plc is a late-stage, clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Prothena is developing antibody-based product candidates that target a number of potential indications, including light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002) and psoriasis and other inflammatory diseases (PRX003). (PRX002) and psoriasis and other inflammatory diseases (PRX003). It is developing antibody-based product candidates that include NEOD001, a humanized monoclonal antibody for the treatment of AL amyloidosis and persistent organ dysfunction diseases; PRX002 for treating Parkinson’s disease and other related synucleinopathies; and PRX003, a monoclonal antibody for the treatment of psoriasis and other inflammatory diseases. Forty-three percent of patients had stable disease. Initiated Phase 1 single ascending dose study of PRX003 in healthy volunteers; PRX002, Prothena’s pipeline has candidates like NEOD001 and PRX003. Additionally, during this quarter, the company initiated a phase I study on PRX003 for the treatment of psoriasis and other inflammatory diseases. Announced successful dosing of the first subject in a Phase 1 single ascending dose study for PRX003, a monoclonal antibody for psoriasis and other inflammatory diseases.

Prothena Corporation Plc: Prothena Reports First Quarter 2016 Financial Results And Provides Update

Prothena: Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases. Ankylosing spondylitis is a long-term inflammatory disease that leads to excessive formation of new bone, particularly in a patient’s vertebrae and joints, which can fuse together. Read the full story Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases Prothena Corporation plc, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today (9 June 2015) announced the successful first human dosing in a Phase 1 clinical trial of its proprietary protein immunotherapy, PRX003. (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). Antibody prx003 and Mcam General. A molecule called melanoma cell adhesion molecule (MCAM) has been identified as a biomarker of disease activity in multiple sclerosis (MS) and a potential therapeutic target for MS and other neuroinflammatory conditions. The results of the current study suggest that anti-MCAM antibodies such as PRX003 may have applications beyond psoriasis, in treatment of neurodegenerative diseases such as multiple sclerosis.

MS patients are told this is a progressive disease and it is, but, clinically speaking, we’ve seen patients improve over long periods of time and continue to improve, study presenter John Marmarou, DPT, MSCS, of Total Rehab & Fitness in Cherry Hill, NJ, told Neurology Advisor. Prothena expects to initiate clinical trials of PRX003 in healthy volunteers by the end of June, and anticipates a study in patients with psoriasis in 2016. Each attack must result in lesions, or patches of inflammation, in different spots on the brain or spinal cord. A number of other equities analysts have also commented on the stock.